Session Chair Profile
M.D., Ph.D., Co-Director of Cancer Genetics and Epigenetics, Johns Hopkins U.
Biography
Dr. Velculescu led the first genomewide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene expression analyses and coined the word transcriptome" to describe the patterns that could now obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. His teams discoveries have led to new FDA approved therapies against PI3K and IDH1, and diagnostic tests for comprehensive tumor profiling. More recently, his group has created noninvasive machine learning liquid biopsy approaches for early detection and monitoring of cancer patients. His work has provided new paradigms for understanding human cancer that have benefited patients worldwide. He has been a Founder and CoCEO of Personal Genome Diagnostics and is Founder and CEO of Delfi Diagnostics.
Talk
Early detection of cancer using cellfree DNA fragmentomes
Cellfree DNA in the blood provides a noninvasive diagnostic avenue for patients with cancer. We have developed an approach called DELFI to evaluate fragmentation patterns of cellfree DNA across the genome using machine learning and low coverage whole genome sequencing. The DELFI method provides a high performing and accessible approach for noninvasive early cancer detection.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Laura J. van 't Veer, UCSF
- PMWC 2024 Award Ceremony
Pioneer Honoree: David Sidransky, Johns Hopkins
Pioneer Honoree: Helmy Eltoukhy
Pioneer Honoree: AmirAli Talasaz, Guardant Health - Utilities of Liquid Biopsy in Biomarker Testing
- Laura Vent Veer, UCSF - Status Quo of Clinical Liquid Biopsy (PANEL)
Chair: Helmy Eltoukhy, Guardant Health
- Sadakatsu Ikeda, Tokyo Medical University
- Heather Parsons, Dana-Farber Cancer Institute
- Sanjay Popat, The Royal Marsden - Liquid Biopsy for Health Monitoring and Disease Prevention (PANEL)
Chair: Anne-Renee Hartman, Adela Bio
- AmirAli Talasaz, Guardant Health
- Heather Parsons, Dana-Farber Cancer Institute
- Mary Pat Lancelotta, Adaptive Bio
- Sylvia Katina Plevritis, Stanford - Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing (PANEL)
Chair: Tom Beer, Exact Sciences
- Wendy Rubinstein, Cancer Screening Research Network (CSRN)
- Sheila D. Walcoff, Goldbug Strategies LLC - Keynote: Pioneering Liquid Nucleic Acids Tumor Fragments in Health and Diseases
- David Sidransky, Johns Hopkins - New Approaches in Liquid Biopsy (PANEL)
Chair: Victor Velculescu, Johns Hopkins
- David Sidransky, Johns Hopkins
- Dan Laudau, NY Genome Center
- Daniel De Carvalho, University of Toronto - Global Implications: A scalable Liquid Biopsy for HPV-related Cervical Cancer (PANEL)
Chair: Debra Fraser-Howze, D. Fraser Associates
- Belinda Nedjai, Wolfson Institute of Population Health
- Elisabeth Adams, Aquarius Population Health Limited - NCI Showcase
- Xiaohui Ni, Early Dx
- Daniel Kim, UCSC
